Pancreatic Cancer Research

ResearcherMedical University of South CarolinaActive in the last 2 years

Clayton S. Lewis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4694-9970; OpenAlex author ID A5068659091. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 7

  1. Targeting Hsp70 Immunosuppressive Signaling Axis with Lipid Nanovesicles: A Novel Approach to Treat Pancreatic Cancer. Co-author DOI 10.3390/cancers17071224↗
  2. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancr… Co-author DOI 10.3390/ijms25052580↗
  3. A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocar… Co-author DOI 10.3389/fonc.2021.691685↗
  4. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.05.013↗
  5. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Co-author DOI 10.18632/oncotarget.11112↗
  6. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.7955↗
  7. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. Co-author DOI 10.1124/jpet.112.199216↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vladimir Y. Bogdanov · 5 shared papers, 2016–2025 · strength 0.71
  2. Xiaoyang Qi · 3 shared papers, 2016–2025 · strength 0.37
  3. Harold W. Davis · 2 shared papers, 2020–2025 · strength 0.33
  4. Jen Jen Yeh · 2 shared papers, 2020–2024 · strength 0.31
  5. Syed Ameen Ahmad · 3 shared papers, 2016–2021 · strength 0.27
  6. Ahmet Kaynak · 1 shared paper, 2025 · strength 0.22
  7. Petr Müller · 1 shared paper, 2025 · strength 0.22
  8. Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.21
  9. Zhengtao Chu · 2 shared papers, 2016–2020 · strength 0.15
  10. Kombo F. N’Guessan · 1 shared paper, 2020 · strength 0.11
  11. Olugbenga Olanrele Olowokure · 1 shared paper, 2020 · strength 0.11
  12. Charles D. Smith · 1 shared paper, 2016 · strength 0.10
  13. Nigel Mackman · 1 shared paper, 2016 · strength 0.05
  14. Alisa S. Wolberg · 1 shared paper, 2016 · strength 0.05
  15. Dusten J. Unruh · 1 shared paper, 2016 · strength 0.05
  16. Georg F. Weber · 1 shared paper, 2016 · strength 0.05
  17. Xiang Liu · 1 shared paper, 2013 · strength 0.03
  18. Thomas Hendrix Beckham · 1 shared paper, 2013 · strength 0.03
  19. Richard R. Drake · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.